Andrew Jones - Eyenovia Chief Officer
| EYEN Stock | USD 0.11 0.02 19.05% |
Executive
Andrew Jones is Chief Officer of Eyenovia
| Age | 53 |
| Address | 295 Madison Avenue, New York, NY, United States, 10017 |
| Phone | 833 393 6684 |
| Web | https://www.eyenovia.com |
Andrew Jones Latest Insider Activity
Tracking and analyzing the buying and selling activities of Andrew Jones against Eyenovia stock is an integral part of due diligence when investing in Eyenovia. Andrew Jones insider activity provides valuable insight into whether Eyenovia is net buyers or sellers over its current business cycle. Note, Eyenovia insiders must abide by specific rules, including filing SEC forms every time they buy or sell Eyenovia'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Andrew Jones over two weeks ago Acquisition by Andrew Jones of 200000 shares of Eyenovia at 0.5501 subject to Rule 16b-3 | ||
Andrew Jones over two months ago Insider Trading |
Eyenovia Management Efficiency
The company has return on total asset (ROA) of (0.9294) % which means that it has lost $0.9294 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (9.1466) %, meaning that it created substantial loss on money invested by shareholders. Eyenovia's management efficiency ratios could be used to measure how well Eyenovia manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of November 2024, Return On Tangible Assets is likely to drop to -1.07. In addition to that, Return On Capital Employed is likely to drop to -1.39. At this time, Eyenovia's Debt To Assets are very stable compared to the past year.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| David Brady | Zura Bio Limited | N/A | |
| MD FACC | ZyVersa Therapeutics | 74 | |
| Verender Badial | Zura Bio Limited | 52 | |
| Daniel MD | Transcode Therapeutics | 72 | |
| Gael Hedou | Sonnet Biotherapeutics Holdings | 52 | |
| Alan Freidman | Transcode Therapeutics | N/A | |
| RN MBA | Transcode Therapeutics | N/A | |
| Melda Oconnell | ZyVersa Therapeutics | N/A | |
| Kiran MBBS | Zura Bio Limited | 51 | |
| Linda Mahoney | Phio Pharmaceuticals Corp | N/A | |
| Theresa Lowry | Zura Bio Limited | 50 | |
| Calais Pharm | Transcode Therapeutics | 65 | |
| Michael Howell | Zura Bio Limited | 47 | |
| Kimberly Davis | Zura Bio Limited | 56 | |
| Gary Whale | Zura Bio Limited | 50 | |
Management Performance
| Return On Equity | -9.15 | ||||
| Return On Asset | -0.93 |
Eyenovia Leadership Team
Elected by the shareholders, the Eyenovia's board of directors comprises two types of representatives: Eyenovia inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Eyenovia. The board's role is to monitor Eyenovia's management team and ensure that shareholders' interests are well served. Eyenovia's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Eyenovia's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Andrew Jones, Chief Officer | ||
| Bren Kern, VP Operations | ||
| Michael Rowe, President CEO | ||
| Tony Cardinale, Vice Sales | ||
| Norbert Lowe, Senior Operations | ||
| Alexander Lobo, Investor Contact | ||
| MD MPH, President, CoFounder | ||
| John CPA, CFO Secretary |
Eyenovia Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Eyenovia a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -9.15 | ||||
| Return On Asset | -0.93 | ||||
| Operating Margin | (516.61) % | ||||
| Current Valuation | 13.81 M | ||||
| Shares Outstanding | 86.44 M | ||||
| Shares Owned By Insiders | 9.99 % | ||||
| Shares Owned By Institutions | 13.73 % | ||||
| Number Of Shares Shorted | 2.14 M | ||||
| Price To Earning | (1.40) X | ||||
| Price To Book | 2.15 X |
Pair Trading with Eyenovia
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eyenovia position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eyenovia will appreciate offsetting losses from the drop in the long position's value.Moving together with Eyenovia Stock
| 0.63 | VALN | Valneva SE ADR Downward Rally | PairCorr |
Moving against Eyenovia Stock
| 0.43 | VERA | Vera Therapeutics | PairCorr |
| 0.42 | VCEL | Vericel Corp Ord | PairCorr |
| 0.35 | SABSW | SAB Biotherapeutics | PairCorr |
The ability to find closely correlated positions to Eyenovia could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eyenovia when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eyenovia - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eyenovia to buy it.
The correlation of Eyenovia is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eyenovia moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eyenovia moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eyenovia can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eyenovia. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Eyenovia Stock, please use our How to Invest in Eyenovia guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eyenovia. If investors know Eyenovia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eyenovia listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.69) | Revenue Per Share 0.001 | Quarterly Revenue Growth 4 | Return On Assets (0.93) | Return On Equity (9.15) |
The market value of Eyenovia is measured differently than its book value, which is the value of Eyenovia that is recorded on the company's balance sheet. Investors also form their own opinion of Eyenovia's value that differs from its market value or its book value, called intrinsic value, which is Eyenovia's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eyenovia's market value can be influenced by many factors that don't directly affect Eyenovia's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eyenovia's value and its price as these two are different measures arrived at by different means. Investors typically determine if Eyenovia is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eyenovia's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.